Product news

Share this article:
The FDA approved Novo Nordisk's NovoSeven RT (coagulation factor VIIa [recombinant] room temperature stable), the first room temperature stable recombinant product available for the treatment of bleeding episodes in patients with hemophilia with inhibitors. NovoSeven RT is a new formulation of NovoSeven (coagulation factor VIIa [recombinant]).

Warner Chilcott and LEO Pharma announced that the FDA has approved the New Drug Application (NDA) for Taclonex Scalp topical suspension. LEO Pharma submitted the NDA for Taclonex Scalp to the FDA in July 2007. Taclonex Scalp contains a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults. Taclonex Scalp is called Xamiol outside the US.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions